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Abstract 
Mutations within STXBP1 have been associated with a range of neurodevelopmental disorders 
implicating the pleotropic impact of this gene. Although the frequency of de novo mutations 
within STXBP1 for selective cohorts with early onset epileptic encephalopathy is more than 1%, 
there is no evidence for a hotspot within the gene. In this study, we analyzed the genomic context 
of de novo STXBP1 mutations to examine whether certain motifs indicated a greater risk of 
mutation. Through a comprehensive context analysis of 136 de novo/rare mutation (SNV/Indels) 
sites in this gene, strikingly 26.92% of all SNV mutations occurred within 5bp upstream or 
downstream of a ‘GTA’ motif (P < 0.0005). This implies a genomic context modulated 
mutagenesis. Moreover, 51.85% (14 out of 27) of the ‘GTA’ mutations are splicing compared to 
14.70% (20 out of 136) of all reported mutations within STXBP1. We also noted that 11 of these 
14 ‘GTA’ associated mutations are de novo in origin. Our analysis provides strong evidence of 
DNA motif modulated mutagenesis for STXBP1 de novo splicing mutations. 
 
Keywords: Genome context, Epilepsy encephalopathy, Loss of function mutation, DNA Motif, 
Mutation etiology. 
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Introduction 
Heterozygous mutations in the brain expressed gene STXBP1 (MIM #602926) are highly 
penetrant for neurodevelopmental phenotypes, with the most striking association with early onset 
epilepsy. This commonly presents as early infantile epileptic encephalopathy (EIEE, also known 
as Ohtahara Syndrome), and often evolves to severe progressive epileptic disorders such as West 
Syndrome and Lennox-Gastaut Syndrome. Other frequently described STXBP1-associated 
neurodevelopmental phenotypes include intellectual disability (ID), Autism Spectrum Disorder 
(ASD), other epilepsy syndromes such as atypical Dravet syndrome, and a variety of movement 
disorders(Barcia et al. 2013; Barcia et al. 2014; Boutry-Kryza et al. 2015; Carvill et al. 2014; Di 
Meglio et al. 2015; Gburek-Augustat et al. 2016; Hamdan et al. 2009; Lopes et al. 2016; Mignot 
et al. 2011; Saitsu et al. 2011; Yuen et al. 2016; Stamberger et al. 2016). STXBP1 is expressed 
specifically in brain(Uddin et al. 2014) and is involved in the synaptic release of 
neurotransmitters, with heterozygous mutations resulting in a reduction of both STXBP1’s 
protein product and the functionally related syntaxin-1, both crucial to the presynaptic 
machinery(Patzke et al. 2015; Yamashita et al. 2016). Its highly penetrant association with 
neurodevelopmental phenotypes is therefore unsurprising, indicating this as an important brain 
development gene. 
 
Mutations in STXBP1 described in the literature so far comprise more than 136 different single 
nucleotide variants (SNVs) and small insertion/deletion (indel) seemingly randomly spread 
throughout the gene: visible clustering is not observed at either the nucleotide or the protein 
domain levels. A similar pattern of dense mutations is seen in other genes, such as CFTR(De 
Boeck et al. 2014) (MIM #602421) and MECP2(Leonard et al. 2017)(MIM #300005), both of 
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which comprise mutation spectra occurring across each gene. The mechanisms whereby these 
mutations occur are largely poorly understood, although a growing body of literature suggests 
that site-specific mutation rates are dependent on their local sequence context, with sequence-
motif associated mutation hotspots identified. Examples of such motifs include CpG 
dinucleotides (Cuddapah et al. 2014; Yang et al. 2016) which are correlated with mutation 
hotspots in mammalian genomes, and repetitive sequences such as homonucleotide runs that are 
involved in certain mutational events. The mechanism by which such motifs mediate mutation is 
not well understood, however, and may involve a particular functional role through their location 
(e.g. splice site) or binding pattern (e.g. known binding of regulatory molecules). Crucially, such 
motifs may offer a target for therapeutics. Indeed, significant progress has been made in cancer 
genetics for compounds that target upstream promotor(Weber et al. 2005) and transcription 
factor binding motifs(Wei et al. 2006).  
 
With this in mind, we were interested in examining the genomic context of STXBP1 mutations to 
elucidate whether their location was characterized by particular recurring motifs. STXBP1 is one 
of the most frequent genes that impacts epilepsy related cases and most of the reported 
pathogenic mutations are de novo in origin which in turns provides a unique opportunity for us to 
investigate the genomic context of such mutations.   
 
MATERIALS AND METHODS 
Mutation Set Collection:  
We have conducted an extensive literature search to identify all STXBP1 mutations. The 
literature has described 162 patients (136 SNVs/indels and 26 CNVs)(Uddin 2017) with rare (not 
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present in 1000genomes and ExAC frequency <0.0001) or de novo heterozygous mutations of 
STXBP1 where 140 variants were reported to be de novo, comprising variants spread across all 
three domains of the gene (Figure 1A). In total, 121 unique single nucleotide variants (SNVs) 
and 15 unique indels have been described. Bearing in mind the clinical importance of this gene, 
STXBP1 represents an important gene for the elucidation of its mutational mechanisms.  
 
Motif Occurrence and Randomized Test: 
To identify motifs that might be part of a template for molecule binding (i.e. transcription 
binding factor, enzyme etc), we have conducted frequency estimation of fixed length (l = 3) 
DNA motifs. For each 3-neucleotide length motif, we have estimated the occurrence within an 
11 base pair window (5 base pair up and downstream) for a mutation. The co-ordinates of the 
136 unique mutations (SNVs and Indels) were used to extract from the human reference genome 
(build GRCh37, hg19) a 5-base pair window upstream and downstream of each mutation using 
procedures implemented in BiomaRt. We then undertook a randomized test by computing the 
occurrences of all possible 3-nucleotide motifs within 5 base pairs (bp) upstream and 
downstream of each of the independently described STXBP1 mutations along with 104 rare 
STXBP1 coding variants from ExAC (none loss-of-function)(Karczewski et al. 2017). This 
database comprises exome data on 60,706 individuals.  A frequency distribution of 10,000 such 
iterations was generated, and a p-value computed by counting the number of draws greater than 
or equal to the actual frequency of particular motifs, with significance set at 0.05.  
 
We also conducted an independent genome context analysis using the Multiple EM for Motif 
Elicitation (MEME) Suite(Bailey et al. 2009). This approach uses an expectation-maximization 
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(EM) algorithm that looks for the most significant patterns, described as those that occur most 
frequently across individual sequences and that have a high rate of similarity. MEME(Bailey et 
al. 2009) reports an E-value, which represents the number of motifs that would be expected by 
chance if letters in the input sequences were shuffled. As such small E-values are very unlikely 
to be random. 
 
Visualization: 
We have used lollipops software(Jay and Brouwer 2016) to map mutations within the protein 
domains. Images were collated using adobe illustrator.   
 
RESULTS AND DISCUSSIONS 
 
The randomized test implicated significant genomic hotspots with clustering of de novo/rare 
mutations around three motifs ‘ACT’(P < 0.0001), ‘GTA’ (P < 0.0001) and ‘TCC’(P < 0.0002) 
(Figure 1B, depicting the genomic context of the 21 unique mutations with ‘GTA’ motifs; 
Figure 1C and supplementary Table S1).  Notably, rare variants (+/-5bp) in ExAC are depleted 
for these motifs. The significance of the ‘TCC’ and ‘GTA’ associated motifs around the STXBP1 
rare/de novo mutations was confirmed using MEME (Figure 1E).  
 
Next, to reduce potential bias introduced by the recurrent nature of some of the mutations, we 
excluded these recurrent mutations and re-analyzed the 92 unique mutations (SNVs and indels). 
This re-analysis confirmed the significance (after multiple corrections) of the ‘GTA’ motif (P < 
0.0005) (Figure 1C). Strikingly, 26.92% of all reported de novo/rare SNV mutations in STXBP1 
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have a ‘GTA’ motif within 5bp upstream or downstream, implicating a genomic context 
dependent mutagenesis. We observed that 51.85% (14 out of 27) of the ‘GTA’ mutations are 
splicing compared to 14.70% (20 out of 136) for mutations overall, with this difference reaching 
statistical significance (Fisher’s Exact Test (FET) P < 0.01, OR = 3.0); we also noted that 11 of 
these 14 ‘GTA’ associated mutations are de novo in origin. Although for all the STXBP1 
mutations there was no enrichment observed for any of the protein domain, the mapping of these 
‘GTA’ associated LOF mutations revealed the co-localization primarily within domain 3A 
(Figure 1A) impacting the disorder region of STXBP1 protein. There was also no evidence for 
any difference in type of epilepsy when comparing ‘GTA’ and ‘non-GTA’ mutations. We have 
analyzed the gender ratio for the 21 unique mutations (27 including recurrent). Gender 
information was available for 19 cases (out of 27) and we found 73.68% (14 cases) are female 
and 26.31% (5 cases) are male (supplementary Table S1). This female bias was also observed in 
the original meta-analysis study of 162 cases(Uddin et al. 2017). 
 
Our finding of a ‘GTA’ motif in STXBP1 that is significantly associated with splicing mutations 
in this gene highlights the importance of genomic context analysis to characterize mutations in 
neuropsychiatric disease. Our finding shows an identifiable genomic context dependent 
mutational mechanism for a neuropsychiatric gene, and the robustness is supported by the 
identification of the same motif using two independent approaches. Previous studies did not find 
any apparent domain specific or genomic locus clustering of STXBP1 mutations. However, our 
genomic context analysis within a +/- 5bp window, demonstrated a motif clustering with splicing 
mutational events.  
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Given the ‘rare variant’ architecture of many neuropsychiatric disorders, with many different 
rare variants spread across individual genes - with each variant conferring susceptibility to the 
disorder, a context analysis such as ours may provide some clues as to the likely underlying 
mutational mechanisms and allow more precise phenotype correlation. Importantly, whilst 
mutations may at first appear randomly spaced along a particular gene, motif analysis may 
indicate otherwise. With the availability of high resolution clinical microarray (Uddin et al. 
2016) and whole genome sequence data(RK et al. 2017), future studies may unravel unidentified 
mutational mechanisms by incorporating motif based analyses.    
 
Although DNA motifs have a significant role in gene regulations, it is a major challenge to find 
the exact mechanism. The role of ‘GTA’ motif into the mechanism of splicing mutation requires 
further investigation. It is anticipated that these motifs may correspond to a protein binding site, 
mediating transcriptional regulation, but further molecular studies – for example, engineering 
motif insertion and deletion - would be required to examine this hypothesis.  Moreover, further 
studies would benefit from examining smaller and larger windows as well as searching for motifs 
of different sizes (for example 2, 4, and 5 bp motifs).  This, however, does carry implication for 
computational burden, which is one reasons we limited our analysis for 3bp motifs. This 
notwithstanding, our study has shown that investigating patterns of mutation, and specifically 
their genomic context, offers the opportunity to begin the scientific process of examining 
mutational mechanisms, ultimately offering new targets for therapeutic interventions.  
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Figure 1: Genomic context analysis if the STXBP1 gene: (A) Distribution of 136 unique 
mutations (top) and those mutations associated with the identified ‘GTA’ motif (bottom). The 
dot size represents the number of recurrent mutations for that specific position. Different 
domains of the protein and the mutation types are color coded; dark blue bars represent the 
disordered regions of protein domains; numbers below each domain represents positions of the 
amino acids. (B) the 21 unique (removing the recurrent) mutations (colored red) associated with 
the ‘GTA’ motif; (C) shows the fraction of mutations associated with ‘GTA’ motif where the 
light blue bar represents the fraction with recurrent mutations and dark blue without; (D) results 
of permutation (Y-axis represents 10,000 randomization) analysis assessing the significance of 
motifs within the STXBP1 gene context; the random distribution of motif occurrences is shown 
in blue bars and the significance of the observed occurrence of motifs within the GTA motif 
associated mutations (without (red vertical line) and with (green vertical line) recurrent 
mutations); (E) MEME motif analysis result for all 136 mutations. The diagram shows 
significant motifs (primarily for “TCC” and “GTA”) identified within the 5bp upstream and 5bp 
downstream of all reported mutation of STXBP1 gene.   
 
 
 
 
 

